

-----  
OMB APPROVAL  
-----

OMB Number:  
Expires:

Estimated average burden  
hours per form.....  
-----

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13D/A

Under the Securities Exchange Act of 1934  
(Amendment No. 3)\*

Healthcore Medical Solutions, Inc.

-----  
(Name of Issuer)

Class A Common Stock

-----  
(Title of Class of Securities)

42220B101

-----  
(CUSIP Number)

Adam D. Eilenberg  
Ehrenreich Eilenberg Krause & Zivian LLP  
11 East 44th Street, 17th Floor  
New York, N.Y. 10017  
(212) 986-9700

-----  
(Name, Address and Telephone Number of Person  
Authorized to Receive Notices and Communications)

March 17, 1999

-----  
(Date of Event which Requires Filing  
of this Statement)

If the filing person has previously filed a statement of Schedule 13G to report the acquisition which is the subject of the Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ].

Note: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent.

\*The remainder of this cover page shall be filed out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Continued on following page(s))

1 NAME OF REPORTING PERSON  
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

SIGA Pharmaceuticals, Inc.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*  
(a) ☐  
(b) ☐

3 SEC USE ONLY

4 SOURCE OF FUNDS\*

WC

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO  
ITEMS 2(d) OR 2(e) ☐

6 CITIZENSHIP OR PLACE OF ORGANIZATION

DE

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER 188,800 (including 93,800 Warrants exercisable at \$6.50 per share)
	8	SHARED VOTING POWER 0
	9	SOLE DISPOSITIVE POWER 188,800 (including 93,800 Warrants exercisable at \$6.50 per share)
	10	SHARED DISPOSITIVE POWER 0

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
188,800 (including 93,800 Warrants exercisable at \$6.50 per share)

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES\*  
☐

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

3.15% (taking into account only shares of Common Stock; 6.07% if also  
including 93,800 Warrants exercisable at \$6.50 per share)

14 TYPE OF REPORTING PERSON\*

CO

\*SEE INSTRUCTIONS BEFORE FILLING OUT!

## Schedule 13D

## Item 1. Security and Issuer

This statement relates to the Class A Common Stock, \$.01 par value ("Common Stock"), of Healthcore Medical Solutions, Inc. (the "Issuer"), which has its principal executive office at 11904 Blue Ridge Boulevard, Grandview, MO 64030.

This statement is filed pursuant to Rule 13d-2(a) with respect to securities owned by the reporting person specified herein as of February 24, 1999 and amends the Schedule 13 D filed on October 15, 1998, Amendment No. 1 filed on January 11, 1999 and Amendment No. 2 filed on February 26, 1999 (collectively the "Schedule 13D"). Except as set forth herein, the Schedule 13D is hereby restated in its entirety.

## Item 3. Source of Funds or Other Consideration

On March 9, and March 17, 1999, the Reporting Person made the following open market sales of an aggregate of 21,000 units of the Issuer's securities ("Units"), each Unit consisting of one share of Common Stock and one currently exercisable Warrant (the "Warrant") to purchase one share of Common Stock (at an exercise price of \$6.50 per share):

Date	No. Units Sold	Sale Price per Unit
3/9/99	1,000	\$1.125
3/17/99	20,000	\$1.125
TOTAL	21,000	

The Reporting Person currently holds 95,000 shares of Common Stock, which represents only 3.15% of the class of Common Stock. However, the Reporting Person also holds the 93,800 Warrants that are included in the Units, which are currently exercisable, even though the exercise price of the Warrants is substantially in excess of the current market price for the Common Stock. The Reporting Person currently has no intention of exercising any of the Warrants. When the shares of Common Stock issuable upon exercise of the Warrants are included with the shares of Common Stock currently held by the Reporting Person, the percentage of the entire class of Common Stock beneficially held by the Reporting Person is 6.07%.

## Item 4. Purpose of Transaction

The Reporting Person disposed of an aggregate of 21,000 Units on March 9 and March 17, 1999 based on favorable market prices for the Units and other business opportunities. The Reporting Person is continuing discussions with management about methods of maximizing or enhancing shareholder value, including the possibility of a combination between the Issuer and the Reporting Person.

While the Reporting Person has no present intention to purchase or sell any additional shares of Common Stock or Units, it may, depending upon its evaluation of the Issuer's business and prospects, determine to increase or decrease or dispose of its position in the Issuer. In making any such determination, the Reporting Person will also take into consideration other available business opportunities and general economic conditions.

## Item 5. Interest in Securities of the Issuer

See Items 7 through 13 of the Schedule 13D/A cover page.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: March 18, 1999

SIGA PHARMACEUTICALS, INC.

By: /s/ JUDSON A. COOPER

-----  
Name: Judson A. Cooper

Title: Chairman of the Board